Home
HelpTest ID: ROS1F Lung Cancer, ROS1 (6q22) Rearrangement, FISH, Tissue
Useful For
Fluorescence in situ hybridization (FISH) testing for ROS1 allows for the detection of most ROS1 rearrangements, therefore, is useful for identifying tumors that may be sensitive to directed therapy
ROS1 FISH testing may also support the diagnosis of inflammatory myofibroblastic tumor, certain cutaneous melanocytic tumors, or other neoplasms when used in conjunction with pathologic assessment
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| _I099 | Interphases, 25-99 | No, (Bill Only) | No |
| _I300 | Interphases, >=100 | No, (Bill Only) | No |
| _IL25 | Interphases, <25 | No, (Bill Only) | No |
| _PADD | Probe, +1 | No, (Bill Only) | No |
| _PB02 | Probe, +2 | No, (Bill Only) | No |
| _PB03 | Probe, +3 | No, (Bill Only) | No |
| _PBCT | Probe, +2 | No, (Bill Only) | No |
Testing Algorithm
This test includes a charge for the probe application, analysis, and professional interpretation of results for one probe set (2 individual fluorescence in situ hybridization probes). No analysis charges will be incurred if an insufficient number of representative cells are available for analysis.
Appropriate ancillary probes may be performed at consultant discretion to render comprehensive assessment. Any additional probes will have the results included within the final report and will be performed at an additional charge.
Method Name
Fluorescence In Situ Hybridization (FISH)
Reporting Name
ROS1 (6q22), FISH, TsSpecimen Type
TissueOrdering Guidance
This test does not include a pathology consultation. If a pathology consultation is requested, order PATHC / Pathology Consultation, and appropriate testing will be added at the discretion of the pathologist and performed at an additional charge.
Multiple oncology (cancer) gene panels are also available. For more information see Hematology, Oncology, and Hereditary Test Selection Guide
Additional Testing Requirements
Confirmation testing for the presence of a possible ROS1 fusion transcript by next generation sequencing to resolve atypical or unbalanced fluorescence in situ hybridization results is available, order MCLNR / MayoComplete Lung Rearrangements, Rapid Test, Tumor.
Shipping Instructions
Advise Express Mail or equivalent if not on courier service.
Necessary Information
1. A pathology report is required for testing to be performed. If not provided, appropriate testing and/or interpretation may be compromised or delayed. Acceptable pathology reports include working drafts, preliminary pathology, or surgical pathology reports.
The following information must be included in the report provided.?
1. Patient name
2. Block number - must be on all blocks, slides, and paperwork
3. Date of collection
4. Tissue Source
3. A reason for testing must be provided. If this information is not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.
Specimen Required
Submit only 1 of the following specimens:
Preferred
Specimen Type: Tissue block
Collection Instructions: Submit a formalin-fixed, paraffin-embedded tumor tissue block. Blocks prepared with alternative fixation methods will be attempted but are less favorable for successful results by FISH testing; provide fixation method used.
Additional Information:
1. Paraffin-embedded specimens can be from any anatomic location (skin, soft tissue, lymph node, etc).
2. Bone specimens that have been decalcified will be attempted for testing, but the success rate is approximately 50%.
Acceptable
Specimen Type: Tissue slides
Slides: 1 Hematoxylin and eosin stained and 4 unstained
Collection Instructions: Submit 4 consecutive unstained, positively charged, unbaked slides with 5 micron-thick sections of the tumor tissue and 1 slide stained with hematoxylin and eosin.
Specimen Minimum Volume
Slides: 1 Hematoxylin and eosin stained and 2 unstained
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Tissue | Ambient (preferred) | ||
| Refrigerated | |||
Clinical Information
The ROS1 gene at 6q22 encodes a tyrosine kinase receptor. Chromosomal rearrangements resulting in fusion of the 3’ aspect of the ROS1 gene with the 5’ aspect of various partner genes was first identified in non-small cell carcinomas of the lung. ROS1 fusions have since been identified in various other neoplasms including but not limited to inflammatory myofibroblastic tumors and cutaneous melanocytic tumors.
Clinical data has shown that tumors harboring ROS1 fusions may be sensitive to directed tyrosine kinase inhibitor therapy.
Reference Values
An interpretive report will be provided.
Interpretation
A result is considered positive when the percent of cells separation of the ROS1 FISH probes exceeds the normal cutoff for the ROS1 FISH probe set.
A positive result is consistent with rearrangement of the ROS1 gene and likely reflects ROS1 fusion with a partner gene. The significance of this finding is dependent on the clinical and pathologic features.
A positive result suggests that the tumor may be responsive to directed therapy in the proper clinical and pathologic context. While results may indicate the potential response to directed tyrosine kinase inhibitors, selection of treatment remains a clinical decision.
A positive result may support a certain diagnosis in a particular clinical and pathologic context.
A negative result does not exclude the presence of a ROS1 fusion or exclude the possible sensitivity to targeted therapy.
Clinical Reference
1. Cui M, Han Y, Li P, et al. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing. Molecular Oncology. 2020;14(11):2787-95
2. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863-870. doi:10.1200/JCO.2011.35.6345
3. Antonescu CR, Suurmeijer AJ, Zhang L, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015;39(7):957-967
4. Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nature communications. 2014;5(1):3116
5. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963-1971
Day(s) Performed
Monday through Friday
Report Available
7 to 10 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88271x2, 88291-DNA probe, each (first probe set), Interpretation and report
88271x2-DNA probe, each; each additional probe set (if appropriate)
88271x1-DNA probe, each; coverage for sets containing 3 probes (if appropriate)
88271x2-DNA probe, each; coverage for sets containing 4 probes (if appropriate)
88271x3-DNA probe, each; coverage for sets containing 5 probes (if appropriate)
88274 w/modifier 52-Interphase in situ hybridization, <25 cells, each probe set (if appropriate)
88274-Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)Â Â Â Â Â Â Â Â
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| ROS1F | ROS1 (6q22), FISH, Ts | 81747-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 52235 | Result Summary | 50397-9 |
| 52237 | Interpretation | 69965-2 |
| 54595 | Result | 62356-1 |
| CG755 | Reason for Referral | 42349-1 |
| 52238 | Specimen | 31208-2 |
| 52239 | Source | 31208-2 |
| 52240 | Tissue ID | 80398-1 |
| 52241 | Method | 85069-3 |
| 55035 | Additional Information | 48767-8 |
| 53821 | Disclaimer | 62364-5 |
| 52242 | Released By | 18771-6 |
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.
mcl-fish